19 clinical trials found.
-
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
The purpose of this study is to test the safety, tolerability, and effectiveness of MRTX849 (called “the study drug” from now on) for advanced cancers ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 1/2a Multicenter Open-Label Non-Randomized First in Human Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Antitumor Activity of DB-1303 in Patients with Advanced/Metastatic Solid Tumors.
You can participate in this study If you are diagnosed with HER2-positive or HER2-expressing advanced/unresectable, recurrent tumor that is refractory to or intolerable with ...Phase
TRIAL ROLE: Sub Investigator
-
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 AS SINGLE-AGENT AND COMBINATION THERAPY IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
This is a research study where doctors are testing a new medicine called XB002 to see if it's safe to take for patients and ...
Phase
TRIAL ROLE: Sub Investigator
-
A Phase 3 Open-Label Randomized Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
This study is being conducted to determine how safe and effective a drug called DZD9008 is compared to standard chemotherapy in patients with locally advanced ...Phase
TRIAL ROLE: Sub Investigator
-
A Modular Open-label Phase I/II Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of EP0031 in Patients with Advanced RET-altered Malignancies
RET alterations mostly happen in lung cancer and thyroid cancer, these alterations can be picked up on molecular testing and can be a target for ...
Phase
TRIAL ROLE: Sub Investigator
-
A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects with Non-Small Cell Lung Cancer
This study is for patients with non-small cell lung cancer (NSCLC). In Part 1 of the study, we will enroll patients to test the safety ...
Phase
TRIAL ROLE: Sub Investigator
-
An open label Phase I dose escalation trial with dose confirmation and expansion of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations
In the first part of the study, we will test the safety, tolerance, and how the body processes a drug called BI 1810631 in patients ...
Phase
TRIAL ROLE: Sub Investigator
-
A Phase I/II Open-Label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics and Anti-Tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 mutation
A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung ...
Phase
TRIAL ROLE: Sub Investigator
-
Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination with VS-6766 and Defactinib in Patients with Previously Untreated Metastatic Adenocarcinoma of the Pancreas
This study is about testing a combination of drugs (gemcitabine, nab-paclitaxel, VS-6766, and defactinib) to treat a type of cancer called pancreatic ductal adenocarcinoma (PDAC ...
Phase
TRIAL ROLE: Sub Investigator
-
A Phase 1/2 First-in-Human Study of DCC-3116 as Monotherapy and in Combination with RAS/MAPK Pathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations
This study is designed for patients who have Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway MutationsThe objective of the study is to ...
Phase
TRIAL ROLE: Sub Investigator
